AgoneX Biopharmaceuticals, Inc. intends to advance its product (AGX-201) and its industry unique technology in order to provide patients with a safe and effective treatment for migraine headaches. Once the company has successfully developed our migraine product, the company intends to develop its proprietary technology for additional indications such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis (MS), Chronic Traumatic Encephalopathy (CTE) and Amyotrophic Lateral Sclerosis (ALS). The company has three (3) issued patents in the U.S. and one (1) issued patent in Japan.
For additional information, please send an email to bd@agonexbio.com.
Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear later in life. Estimates vary, but experts suggest that more than 6 million Americans, most of them age 65 or older, may have Alzheimer’s.
Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.
Dementia is the loss of cognitive functioning “” thinking, remembering, and reasoning “” and behavioral abilities to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for help with basic activities of daily living.
Alzheimer’s costs our nation an astonishing $345 billion per year, including $222 billion in costs to Medicare and Medicaid. If we continue along this trajectory, Alzheimer’s is projected to claim the minds of 13.8 million seniors by 2060 and nearly surpass $1 trillion in annual costs by 2050. (Source: Collins’ Bipartisan Bills to Bolster Alz… | U.S. Senator Susan Collins (senate.gov) )
Parkinson’s Disease is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed, but not halted, by treatment. Despite extensive research in the area of PD, the precise pathogenesis remains largely unknown. Parkinson’s Disease is characterized by motor and nonmotor (cognitive and limbic) deficits. The economic burden of Parkinson’s disease is at least $14.4 billion a year in the United States, and the prevalence of Parkinson’s will more than double by the year 2040.